insights_auto
Why is ALMKT down 3.48%?
Dive Deeperchevron_right
ALMKT:EPA
Mauna Kea Technologies SA
€0.092
arrow_downward
-3.48%(-0.0033) 1D
Nov 3, 1:43:21 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.09
High
€0.10
Low
€0.09
Mkt. cap
17.33M
Avg. vol.
495.55K
Volume
495.24K
P/E ratio
0.78
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.09
High
€0.10
Low
€0.09
Mkt. cap
17.33M
Avg. vol.
495.55K
Volume
495.24K
P/E ratio
0.78
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
marketscreener.com
·
5 minutes ago
Dow Futures Fall, Treasurys Yields Rise Heading Into Midterms -- Update
Bloomberg
·
30 minutes ago
UBS Traders See ‘Combustible Setup’ for S&P 500 Rally After Vote
Barron's
·
48 minutes ago
S&P 500 Futures Decline in Premarket Trading; Ascendis Pharma, Madrigal Pharmaceuticals Lead
Yahoo Finance
·
1 hour ago
2 S&P 500 stocks to consider right now and 1 we find risky
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA